Flywheel offers an enterprise imaging platform that aggregates, curates, and analyzes medical imaging and video data at scale, helping customers streamline research workflows and prepare AI-ready datasets. During 2025 the company broadened its product suite with a video viewing and annotation tool and launched Flywheel Validated, which supports 21 CFR Part 11–compliant imaging workflows for clinical trials. Its customer roster now includes 10 of the top 20 global pharmaceutical companies and 10 of the top 20 academic medical centers. Commercial traction was strong, with 43 % year-over-year growth in new business, a 40 % increase in committed revenue, and annual recurring revenue from pharma and device customers up 106 %. Net revenue retention exceeded 110 %, underscoring sticky usage and expansion within existing accounts. Backers of the company include Novalis LifeSciences, 8VC, NVIDIA, Microsoft, Novartis, and Intuitive Surgical. The new capital will be used to accelerate product innovation and further penetrate the clinical trial and AI model development markets.

Total raised

$119M

Funding rounds

4

Latest round

Equity

Latest activity

Jan 2026